RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Study shows [177Lu]Lu-PSMA is safe and effective for elderly patients with mCRPC, improving PSA response and overall survival
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
Dr. Morris discusses a phase 1 study of JNJ-6420 for patients with mCRPC who received at least prior ARPI.
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Dr. Kishan discusses new research presented at the 2024 PSMA Conference.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.